3 results
Not approvedWill not start
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
Approved WMORecruiting
The primary objective of this study is to further evaluate the safety and effectiveness of the MRI-guided TULSA-PRO device intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
Approved WMORecruiting
To compare the progression free survival and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.